Clinical trials: Sitagliptin
Diabetes Mellitus, Type 2
Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension
The objective of the current study is to investigate the safety and efficacy of BI 10773 in 2 different doses compared to Metformin or to Sitagliptin given for 78 weeks in different modalities of treatment in patients with type 2…
- Trial name
- NCT00881530
- Testing
- BI 10773, Metformin, Sitagliptin
- Where
- 137 sites in United States, Austria and 19 more
- Volunteers
- 660 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes
The aim of this trial is to evaluate the safety of single doses of a study drug known as LY3325656 that is given orally to healthy participants and participants with type 2 diabetes.
- Trial name
- NCT03115099
- Testing
- LY3325656, Liraglutide, Sitagliptin
- Where
- 2 sites in Singapore
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Liver Insufficiency
A Study of MK0431 in Patients WIth Hepatic Insufficiency (0431-017)(COMPLETED)
A study to compare the plasma concentrations of MK0431 at different times in patients with hepatic insufficiency vs healthy control subjects.
- Trial name
- NCT00696826
- Testing
- sitagliptin phosphate
- Volunteers
- 20 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency
This clinical trial is designed to provide additional information on the safety and tolerability of vildagliptin (50 mg once daily (qd)) and sitagliptin (25 mg qd) when used in patients with type 2 diabetes mellitus(T2DM) and…
- Trial name
- NCT00616811
- Testing
- vildagliptin, Sitagliptin
- Where
- 79 sites in United States
- Volunteers
- 148 people
- Sponsor
- Novartis
Bioequivalance
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100 mg/1000 mg in Healthy Subjects, Fed Study.
Prospective, longitudinal, single-dose, randomized, open-label, crossover 2x2, two treatments, two periods, two sequences controlled clinical study
- Trial name
- ACL25-IC005 (NCT07763964)
- Testing
- Janumet XR, Sitagliptin/Metformin FDC
- Where
- Mexico
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- ADIUM
Type 2 Diabetes Mellitus
A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics
This study is intended to evaluate the pharmacodynamics, safety, and tolerability of LX4211 when administered concurrently with sitagliptin (Januvia®) in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT01441232
- Testing
- LX4211, Januvia®
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Lexicon Pharmaceuticals
Type 2 Diabetes Mellitus
Exploratory Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin (CGMS Study)
This is a randomized, double-blind, active control, parallel group, exploratory phase 4 study to compare the effect of teneligliptin versus sitagliptin on glucose variability when added on to metformin in patients with…
- Trial name
- NCT02512523
- Testing
- Teneligliptin, Sitagliptin
- Where
- South Korea
- Volunteers
- 39 people
- Sponsor
- Handok Inc.
Type 2 Diabetes Mellitus
Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to determine the safety and efficacy of MK-0431/ONO-5435 in patients with Type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy and metformin as monotherapy
- Trial name
- NCT00363948
- Testing
- Sitagliptin phosphate
- Where
- 8 sites in Japan
- Volunteers
- 188 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2
The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who are receving treatment with metformin and pioglitazone and…
- Trial name
- NCT01106690
- Testing
- Canagliflozin, Sitagliptin, Metformin
- Where
- 83 sites in United States, Canada and 9 more
- Volunteers
- 344 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes Mellitus, Type 2, Renal Insufficiency
Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)
This clinical trial is designed to provide additional information on the safety and tolerability of vildagliptin (50 mg once daily (qd)) and sitagliptin (25 mg qd) when used in patients with type 2 diabetes mellitus(T2DM) and…
- Trial name
- NCT00770081
- Testing
- vildagliptin, sitagliptin
- Where
- 87 sites in United States
- Volunteers
- 75 people
- Sponsor
- Novartis
Type 2 Diabetes Mellitus
Evaluation of Low Blood Sugar Events in Participants With Diabetes (MK-0431-401)
This is a multi-center, observational, retrospective and cross-sectional study to be conducted in a cohort of consecutively selected participants with Type 2 diabetes mellitus (DM) who have been treated with sulphonylurea (SU)…
- Trial name
- NEEDS (NCT01285076)
- Testing
- Other: Retrospective chart review; one participant encounter visit.
- Where
- Taiwan
- Volunteers
- 834 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)
This trial is designed to evaluate, in adult participants with Type 2 diabetes mellitus (T2DM) and inadequate glycemic control on sub-maximal metformin mono-therapy (1000 mg/day), the effect of up-titration of metformin plus the…
- Trial name
- NCT02791490
- Testing
- Sitagliptin, Metformin IR
- Volunteers
- 458 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
The purpose of this study is to evaluate the effect of TAK-875 (fasiglifam) in combination with sitagliptin on glycemic control in adults with type 2 diabetes.
- Trial name
- NCT01829464
- Testing
- TAK-875
- Where
- 86 sites in United States, Argentina and 1 more
- Volunteers
- 90 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD)
The present study aims to evaluate the efficacy and safety of different combinations of oral antidiabetics in patients with inadequate glycemic control on metformin monotherapy.
- Trial name
- TRIAD (NCT06560333)
- Testing
- N0892
- Where
- Brazil
- Sponsor
- Eurofarma Laboratorios S.A.
Type 2 Diabetes Mellitus
Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to determine the safety and efficacy of MK-0431/ONO-5435 in patients with Type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy and glimepiride as monotherapy
- Trial name
- NCT00363519
- Testing
- Sitagliptin phosphate
- Where
- 8 sites in Japan
- Volunteers
- 195 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Bioequivalence
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 50 mg/1000 mg in Healthy Subjects, Fed Study.
Prospective, longitudinal, single-dose, randomized, open-label, crossover 2x2, two treatments, two periods, two sequences controlled clinical study
- Trial name
- ACL25-IC003 (NCT07763912)
- Testing
- Janumet XR, Sitagliptin/Metformin FDC
- Where
- Mexico
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- ADIUM
Type 2 Diabetes
MK-0431/ONO-5435 Phase III Clinical Trial-Rapid-acting Insulin Secretagogue Add-on Study in Patients With Type 2 Diabetes
This Phase III clinical trial will examine the safety, tolerability, and efficacy of the addition of MK-0431/ONO-5435 to Japanese patients with Type 2 Diabetes mellitus who have inadequate glycemic control on diet/exercise…
- Trial name
- NCT01517321
- Testing
- MK-0431/ONO-5435
- Where
- 6 sites in Japan
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus
Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin
The purpose of this study is to demonstrate the safety and tolerability of dutogliptin over 52 weeks.
- Trial name
- NCT00998686
- Testing
- dutogliptin, sitagliptin
- Where
- 44 sites in United States, Argentina and 4 more
- Volunteers
- 650 people
- Sponsor
- Phenomix
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin
This trial will be conducted in Africa, Asia, North America and South America. The aim of this clinical trial is to compare NN1250 (insulin degludec) with sitagliptin, as add-on to subject's own current oral antidiabetic (OAD)…
- Trial name
- BEGIN™ (NCT01046110)
- Testing
- insulin degludec, sitagliptin
- Where
- 93 sites in United States, Argentina and 5 more
- Volunteers
- 458 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes
This study will investigate the efficacy and long term safety and tolerability of BI 10773 in type 2 diabetic patients.
- Trial name
- NCT01289990
- Testing
- BI 10773, Sitagliptin 100mg
- Where
- 243 sites in United States, Belgium and 17 more
- Volunteers
- 2,705 people
- Sponsor
- Boehringer Ingelheim